저자: Kevin · 외국인
요약 보기
AI가 헬스케어에 미치는 영향을 설명. Moderna(10/24 토요일 Phase 3 암백신 데이터 발표 임박, AI로 개인맞춤 mRNA 백신 제작 기간 단축, 목표가 220 상향 언급)를 핵심 촉매로 제시하며 135~145 부근 매수했다고 밝힘. Eli Lilly는 시총 1.22조달러, PEG ~1.9로 상대적 저위험 대안으로 언급. Tempus AI는 2028 흑자 전망 및 일회성 주식 평가이익 102백만달러 지적 후 직접 투자하지 않는다고 함. 영상 중반 이후 광고(소송 환급, 구독 멤버십) 비중이 큼.
다듬은 글
The next sector of artificial intelligence may be hidden in plain sight, and we should talk about some of the breakthroughs that are happening, as well as what will happen this Saturday that could be another catalyst for a particular stock that is showing quite good results. Here we talk about how artificial intelligence is already affecting and will affect the stocks of healthcare companies.
Some of the stocks we'll touch on here are Tempus AI, Moderna, and Eli Lilly. Now I want to be clear about these three, I have experience with two of them. As always, we always send a message about our portfolio transparency to everyone at reinvest1.com. In this membership, you pay once, you get lifetime access.
You can read all about it at reinvest1.com. But for now, let's focus on artificial intelligence in medicine. So, the first thing to know is that Moderna has a meeting this Saturday. This will be a presentation, they are intentionally holding it when the market is closed. This will be a presentation on October 24th.
This is the immediate catalyst, and this is a phase 3 data update for their cancer therapy, which is a partnership between Moderna and Merck's Keytruda cancer drug, or immunotherapy drug, to fight stage 4 melanoma and minimize the risk of metastasis throughout the body. So, how does it work? Well, how does it work, and I'm going to simplify it because otherwise it gets really boring.
But basically, how does AI fit into this world ? Good? That's really the part we want to talk about with Moderna, and then I'll talk about Tempus AI, and then I'll talk about Eli Lilly to show you how AI is touching some of them, and also some of the startups that are working on artificial intelligence, which is kind of what prompted some of us to talk about this this morning on our live broadcast.
But look at this. This is a board. Good. So, what does Moderna do? Moderna essentially says, “Hey, let’s look at someone’s cancer. So, we'll take a solid cancer cell and surgically remove part of it. " We'll do a biopsy." So, we'll take a biopsy of, you know, a cancer cell. And then we'll do this, we'll search for it genomically...Wow!
We're going to do genomic sequencing, which, you know, is a very long chain of genetic data. Think about T, A, and K. Remember biology days, right? And we're going to try to find in this cancer cell the pieces of this genome that we can eliminate, which obviously means we don't want to affect the parts of this genome that, if we targeted them, would kill you.
Of course, this is a problem. We want to affect parts of this genome that are unique to this cancer cell. The problem is that cancer cells are constantly mutating. They are constantly changing. So this basic genome is very variable. So, we're going to affect 32 different slices. And if even one of these slices survives, we can still affect that cancer cell.
We're going to inject these little slices into you probably seven times over a 12- month cycle. And we're going to train your body. We won't go into the exact science , because this gets a little deeper into protein folding and predicting what ultimately happens in your lymph nodes. Essentially, small carriers will learn from these 32 slices.
And they'll take these 32 little slices and attach them to their outer part. They'll take it into your lymphatic system and say, " See all these little spikes?" Destroy them. Destroy these little squirrels we carry. Identify and destroy them." And then your lymphatic system will say, “We don’t like this.
We're going to...We're going to...I'm going to ...I'm going to ...I'm going to...I'm going to... I'm going to...I'm going to...I'm going to make an angry face . That's it. Angry grimace. We're going to go after these little spikes." Okay, but these spikes are really hard to identify, and that's where artificial intelligence comes in.
Because these guys can go all over your body and identify where they are and track down and destroy that cancer cell, preventing it from metastasizing throughout the rest of your body, right? And the whole idea is that even if that cancer cell mutates or evolves, as long as we have one of those pieces left, we can still identify it.
That's the idea. The problem is that this identification process used to take about 60 days, and you would get two of them. Maybe two slices. OK? This has changed thanks to AI. Now AI comes along and says, "We can do a lot of this in about 2 weeks." And we can get 32 predicted slices that we think will actually kill the cancer, but God doesn't.
Both of these things are important, right ? So AI is speeding up the time for this, and this meeting, which will be held on Saturday the 24th, should provide a lot more information about how well this phase 3 cancer trial is going and how the therapy is progressing . Of course, you know, that could also be bad, but considering that the presentation is on Saturday, a lot of people are optimistic that they'll put on a pretty good show.
Uh, and I personally deal with Moderna shares. I am very happy about this. Uh, we didn't buy them until, uh, this news about phase three. We were actually waiting for the initial momentum to die down. We bought it somewhere around here, around 135-145. So I'm really happy for Moderna because artificial intelligence allows more patients to use it faster , while lowering its cost.
This is a long-term goal. Ultimately, there is hope that such treatments can then be extended to other types of cancer, not just melanoma or other solid tissue cancers, but to others in general. Because this same treatment can already work for lung cancer, where there are real tumors, maybe even for breast cancer, but it would be good to see this extended even to other types of cancer, like blood cancer, leukemia, right ?
In any case , Moderna is a special promotion in this field. These stocks are getting very expensive due to a single treatment. I mean, they offer others, but this is just an example of how AI can improve these actions in healthcare. However, there is a big risk of one test here. And this is where other companies like Tempus, startups that you might be able to invest in, or Eli Lilly become very interesting.
Because it's not just a company like Moderna that does these things. There was a great article in the New York Times that referenced a study that this new company called Well, Startups Are Doing is doing , called Radical Digit. And this was exactly that article. If you or your child grew up on social media for years and ha jury developeir app didn't share these risks, prioritizing profits.
A recent historic verdict highlights the implications of these decisions. Now Morgan& Morgan is taking steps to hold these platforms accountable for the harm they cause. Follow the link in my bio to take the short test and you could be eligible for a potential refund of over $1,000. This is quite easy to do.
Follow the link in the description and ould potentially get over $1,000 in reimbursement. That's what the article was about. They're actually claiming to be using artificial intelligence to help them identify, like I showed you these little spikes, only now instead of spikes they're going to try to use artificial intelligence to genetically engineer or match phages, which are the enemies of bacteria.
And these phages will have their little legs modified, you know, enhanced by artificial intelligence so that they can properly attach to the harmful bacteria that someone is infected with and kill those harmful bacteria. Now you might be thinking, why not just use an antibiotic? Well, several reasons.
First, antibiotics kill a lot of bacteria, including good bacteria, but beyond that, we actually see that the number of deaths from antibiotic resistance in the United States is roughly equivalent to the number of deaths from car accidents. In 2025, there were an estimated 36,640 deaths in the United States from traffic accidents compared to 35,000 directly linked to antimicrobial-resistant infections.
This is crazy, because people are literally dying from bacterial infections that we can't treat because these bacteria are resistant to treatment. Artificial intelligence, through a company called Radical Numerics, could potentially be used to turn these small phages, similar to bacteria-killing viruses, into weapons.
And we can't just predict which phage will save your life, and do it quickly, before you die, because that's a different matter. If it takes months to do the work manually , you're already dead. So AI speeds up the process. This is another example of how AI is impacting healthcare. Or you can engineer phages to do exactly what you want them to do by manipulating their little attachment points, the little legs of these viruses, if you will.
I'm trying... Again, I'm simplifying. OK. That's cool for this particular lab, but what about other games? For example, how about a software game? If we consider software, then there is Tempus. Tempus is not expected to be profitable until 2028. They reported a profit, but that was mostly because their income statement reflected a huge number of shares.
So, um, less- less ideal because, you know, it says less about the underlying business. I have no problem with the company making money or investing in stocks. I think it's a good use of, um, diversifying some of the funds they have and accessing other aspects of the market while still doing what they do.
But, you know, we have to be clear that when they report positive net income last quarter, it's actually because they got about $102 million in stock appreciation. Good. And that doesn't necessarily mean they sold, it just means they overvalued those profits at market price. Here is a company that is developing its artificial intelligence business at the fastest pace.
They are growing their business with artificial intelligence, data, and applications by 28%. Business legacy is growing by about 20%. Their costs and profitability are actually better in the AI space , and that's the side that's growing faster. So there is great hope for a company like Tempus AI, ticker TEM.
However, I don't invest in them. I still think it's potentially too early to say that they're going to be, you know, data and application winners. So I want to show you another scenario. The next scenario has a PEG ratio of about 1.9, which is kind of a magic number where, I like, I like, I like , I like, I like, less than two for some of these service providers.
And this is this company right here. This is Eli Lilly. Eli Lilly is already a company with a market capitalization of over $1 trillion, but I call them the S&P 500 of artificial intelligence. Because this meeting on Saturday could end horribly for Moderna, and then the stock would fall back to $140 and you would lose all your profits.
And it could be great too, and it's a $300 stock. And this is your high volatility bet. Your less risky, less YOLO bet, in my opinion, is a bet similar to Eli Lilly. Obviously, nothing in this video is personalized financial advice. My goal is simply to provide perspective, data, and insight. This is the same thing we do at Reinvest One.
We invite you to join us. You can go to reinvestone.com, join us here. You can become part of the Alpha membership. You will receive all notifications about your trading portfolio. You will receive our Alpha Report every morning. You will receive our stock terminal later this year. I ca n't wait for it to come out.
So, that will be out later this year. This will be very, very useful. Essentially, we're trying to create everything that Kevin would use, for example, in a Refinitiv or Bloomberg terminal, in one nice package so that you can get it in a Reinvest terminal for a fraction of the price. You get built-in Homes AI, built-in of course participants, and our A Gen Tech AI Business Plan for businesses and consumers, which is really exciting.
Many interesting things await here. So, a really good package you're getting at Reinvest 1.com right now. Well, yes, but anyway, back to Eli Lilly . I see Eli Lilly as a definite S&P 500 player in healthcare. And the reason I say that is, instead of picking a bunch of individual players in healthcare, you can look at Eli Lilly as anyone who starts to succeed and becomes big, Eli Lilly just comes in and goes, " You know what?
We're going to buy your software. We're going to buy your startup." They are really good at acquisitions. They are an acquisition machine. I mean, they literally, you know, absorb every competitor they can get. And they have the capital to do it. They have the reputation to do it. They have the profitability to do so .
Uh, they have the, uh , market capitalization to do it. I mean, you know, over $1 trillion in market capitalization. Yes, $1.22 trillion in market capitalization. This is a fairly large company. Er, and er, and quite rightly so. So, I think this is the least risky position, and I still think their valuation is reasonable, even though they've already performed very well.
So, that's my take on how healthcare is impacting AI, and some of the things I'll be looking at this weekend, especially in light of the Moderna presentation. So I'm very happy about that. Uh , the target price from Bank of America has now increased to 220, uh, for Moderna. And, uh, keep in mind, Moderna what?
The company has a market capitalization of $70.93 billion now. So, post-COVID, and this is actually what was sustaining their revenue post-COVID, their growth prospects really plummeted, and it turned into a business that was just milking the COVID mRNA, uh, vaccine. And they didn't have any real vertical growth until the third phase, which people call the cancer vaccine.
It's truly therapy. Uh, but, uh, but I'm personally very, very excited about this. Uh, it would be like if you were to step back a little bit from the stock chart, it would show you the virality that this company used to have, but doesn't have. Unless, of course, they have a bad report on Saturday, then it just goes back to the floor.
So, not personalized financial advice. Enjoy us at reinvestor1.com. Uh, and I know there's a comment here: "Don't go after this." Go ahead, fill your mug, and, uh, make us watch the commercials. We do n't want to." It's very nice of you to say that, but I have about a million and a half things to do .
So I have one very strong message for you. Especially for you. Oh, frien, friend. Your boyfriend Kevin. Do you like this .
댓글 0